

Electronic Supporting Information

Visible-Light-Induced Bifunctionalisation of (Homo)Propargylic Amines with CO₂ and Arylsulfonates

Mandapati Bhargava Reddy^{a,b} and Eoghan M. McGarrigle^{*a,b}

^aCentre for Synthesis & Chemical Biology, *UCD School of Chemistry, University College Dublin, Belfield, Dublin 4, Ireland*

^bA2P CDT in Sustainable Chemistry and BiOrbic Bioeconomy SFI Research Centre, *University College Dublin, Belfield, Dublin 4, Ireland.*

email: eoghan.mcgarrigle@ucd.ie

<u>S.No</u>	<u>Table of contents</u>	<u>Pages</u>
1	General considerations	S2
2	General procedures and spectral data	S3-S13
3	Intermediate trapping experiment	S14
4	X-ray crystallographic studies of compound 4a	S15-S18
5	References	S18
6	Copies of ¹ H and ¹³ C NMR spectra	S19-S76

1. General considerations

Chemicals were purchased and used without further purification unless otherwise stated. The ^1H and ^{13}C NMR spectra were recorded in CDCl_3 on Varian VNMR spectrometers (400 and 500 MHz for ^1H NMR; 101 and 126 MHz for ^{13}C NMR) with TMS as an internal standard. Mass spectra were recorded on Agilent-6546-QToF spectrometer. TLC was performed on using Merck pre-coated TLC plates (Merck 60 F₂₅₄) and detected under UV light. Flash column chromatography (FCC) was performed using either silica gel [Davisil, 230-400 mesh (40-63 μm)] or using a Biotage Isolera® UV-VIS Flash Purification System Version 2.3.1 with Sfar Silica HC D (20 μm) prepacked silica cartridges.

Details of Light source:

Manufacturer: Kessil; Model: PR160L; Wavelength: 456 nm, Distance: 5 cm. Manufacturer gives spectral width as ~430-510 nm with radiant flux max at 456 nm of ~0.3 W/nm and ‘average intensity of PR160 series’ as 399mW/cm² (measured from 1 cm distance), max power consumption 50W.




Fig. S1. Reaction setup for photochemical carboxylative sulfonylation reactions.

2. General procedures and spectroscopic data

2.1 General procedure for synthesis of *N*-Benzylpropargylamine (1aa-1au).

Propargylamines were synthesized using the literature procedure.^{1,2}

Propargyl bromide (1 equiv.) was added dropwise to the solution of benzylamine (6 equiv.). The reaction was stirred 15 h at room temperature and then 2 M NaOH and Et₂O were added. The layers were separated and the aqueous layer was extracted with Et₂O. The combined organic layers were dried over Na₂SO₄ and then evaporated under reduced pressure. The crude product was purified by flash column chromatography using EtOAc/pentane as an eluent to furnish the corresponding *N*-benzylpropargylamine.

2.2 General procedure for synthesis of *N*-Benzyl homopropargylamines (1ba-1bh).^{2,3}

Homopropargylamines were synthesized using the literature procedure.^{2,3}

To a solution of homo propargyl alcohol (1 equiv.) and triethylamine (1.5 equiv.) in DCM (7 mL/mmol) was added methanesulfonyl chloride (1.2 equiv.) dropwise at 0 °C. The reaction mixture was allowed to stir at 0 °C for 1 hour and then quenched with 1N aqueous HCl. The aqueous layer was extracted with DCM and the organic layers were washed with brine and dried over Na₂SO₄. Crude mesylate was dissolved in DMSO (2 mL/mmol). The benzyl amine (2 equiv.) and sodium iodide (0.1 equiv.) were then added and the reaction mixture was stirred at 50 °C for 16 hours. The solution was then cooled to room temperature and diluted with saturated aqueous NaHCO₃ and ethyl acetate. The phases were separated and the aqueous layer extracted with ethyl acetate. The organic layer was dried over Na₂SO₄ and then evaporated under reduced pressure. The crude product was purified by flash column chromatography using EtOAc/pentane as an eluent to furnish the corresponding *N*-benzyl homopropargylamine.

2.3 General procedure A for carboxylative sulfonylation


The reaction tube was charged with propargylamine (0.14 mmol), sodium arylsulfinate (0.21 mmol), Cs₂CO₃ (0.28 mmol) and Ru(bpy)₃Cl₂·6H₂O (2 mol%) in DMSO (2 mL). The mixture was stirred under blue LED irradiation for 14 hours. Then, the reaction mixture was quenched with H₂O (20 mL) and aqueous layer was extracted with ethyl acetate (2x10 mL). The combined organic layer was dried over Na₂SO₄ and then evaporated under reduced pressure. The crude product was purified by flash column chromatography using EtOAc/pentane as an eluent to furnish the corresponding final product.

Note: the lights heat the reaction slightly. The reaction temperature was measured to be 27 °C. A control experiment carried out at 27 °C without light gave no reaction.

2.4 Scale-up reaction


A 50 mL round bottom flask was charged with *N*-benzylprop-2-yn-1-amine (1.40 mmol), Sodium benzenesulfinate (2.10 mmol), Cs₂CO₃ (2.80 mmol) and Ru(bpy)₃Cl₂·6H₂O (2 mol%) in DMSO (15 mL). The mixture was stirred under blue LED irradiation for 24 hours. Then, the reaction mixture was quenched with H₂O (75 mL) and aqueous layer was extracted with ethyl acetate (2x20 mL). The combined organic layer was dried over Na₂SO₄ and then evaporated under reduced pressure. The crude product was purified by flash column chromatography using EtOAc/pentane 2:3 as an eluent to furnish the 3-benzyl-5-(tosylmethyl)oxazol-2(3*H*)-one as a white solid (346 mg, 73%).

3-Benzyl-5-(tosylmethyl)oxazol-2(3*H*)-one (3a)




3a (40 mg) was synthesized following general procedure A; white solid; 84% yield (eluent: EtOAc/Pentane = 2:3); ¹H NMR (400 MHz, CDCl₃): δ 7.64 (d, *J* = 8.3 Hz, 2H), 7.42-7.32 (m, 3H), 7.27 (d, *J* = 8.1 Hz, 2H), 7.26-7.20 (m, 2H), 6.43 (s, 1H), 4.66 (s, 2H), 4.13-4.08 (m, 2H), 2.42 (s, 3H); ¹³C NMR (101 MHz, CDCl₃): δ 154.6, 145.5, 134.9, 134.8, 130.0, 129.1, 128.6, 128.6, 128.4, 128.0, 116.1, 54.0, 47.8, 21.7; HRMS: [M+H]⁺ calculated for C₁₈H₁₈NO₄S: 344.0956; found: 344.0951.

3-(1-Phenylethyl)-5-(tosylmethyl)oxazol-2(3*H*)-one (3b)




3b (33 mg) was synthesized following general procedure A; white solid; 68% yield (eluent: EtOAc/Pentane = 2:3); ¹H NMR (500 MHz, CDCl₃): δ 7.64 (d, *J* = 8.3 Hz, 2H), 7.41-7.33 (m, 3H), 7.29-7.26 (m, 4H), 6.46 (s, 1H), 5.26 (q, *J* = 7.1 Hz, 1H), 4.11 (s, 2H), 2.44 (s, 3H), 1.67 (d, *J* = 7.1 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃): δ 154.1, 145.5, 139.3, 134.7, 129.9, 129.0, 128.5, 128.5, 128.4, 126.5, 113.9, 54.1, 52.8, 21.7, 19.2; HRMS: [M+H]⁺ calculated for C₁₉H₂₀NO₄S: 358.1113; found: 358.1108.

3-(1-Phenylpropyl)-5-(tosylmethyl)oxazol-2(3H)-one (3c)




3c (34 mg) was synthesized following general procedure A; white solid; 65% yield (eluent: EtOAc/Pentane = 2:3); ^1H NMR (400 MHz, CDCl_3): δ 7.60 (d, $J = 8.3$ Hz, 2H), 7.38-7.31 (m, 3H), 7.27-7.23 (m, 4H), 6.52 (s, 1H), 4.93 (dd, $J = 9.0, 6.8$ Hz, 1H), 4.11 (s, 2H), 2.41 (s, 3H), 2.12-1.97 (m, 2H), 0.94 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 154.4, 145.5, 138.6, 134.6, 129.9, 129.0, 128.6, 128.5, 128.4, 126.9, 113.8, 59.2, 54.1, 26.4, 21.7, 10.9; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{20}\text{H}_{22}\text{NO}_4\text{S}$: 372.1269; found: 372.1265.

3-Phenethyl-5-(tosylmethyl)oxazol-2(3H)-one (3d)




3d (40 mg) was synthesized following general procedure A; white solid; 82% yield (eluent: EtOAc/Pentane = 2:3); ^1H NMR (400 MHz, CDCl_3): ^1H NMR (500 MHz, CDCl_3): δ 7.66 (d, $J = 7.9$ Hz, 2H), 7.33-7.28 (m, 4H), 7.26-7.24 (m, 1H), 7.17 (d, $J = 7.4$ Hz, 2H), 6.35 (s, 1H), 4.08 (s, 2H), 3.80 (t, $J = 7.1$ Hz, 2H), 2.96 (t, $J = 7.1$ Hz, 2H), 2.45 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3): δ 154.4, 145.6, 137.1, 135.1, 130.0, 128.9, 128.7, 128.4, 128.0, 127.1, 116.8, 53.9, 45.5, 35.0, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{20}\text{NO}_4\text{S}$: 358.1113; found: 358.1110.

3-(2-Methoxybenzyl)-5-(tosylmethyl)oxazol-2(3H)-one (3e)




3e (42 mg) was synthesized following general procedure A; white solid; 79% yield (eluent: EtOAc/Pentane = 2:3); ^1H NMR (400 MHz, CDCl_3): δ 7.62 (d, $J = 8.3$ Hz, 2H), 7.32 (td, $J = 7.9, 1.8$ Hz, 1H), 7.23 (app td, $J = 7.9, 3.3$ Hz, 3H), 6.98-6.87 (m, 2H), 6.56 (s, 1H), 4.66 (s, 2H), 4.08 (s, 2H), 3.85 (s, 3H), 2.40 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 157.3, 154.6, 145.4, 134.9, 130.5, 130.1, 129.9, 128.4, 127.8, 123.2, 120.9, 117.1, 110.7, 55.4, 54.1, 43.2, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{20}\text{NO}_5\text{S}$: 374.1062; found: 374.1059.

3-(3-Methoxybenzyl)-5-(tosylmethyl)oxazol-2(3H)-one (3f)




3f (35 mg) was synthesized following general procedure A; white solid; 66% yield (eluent: EtOAc/Pentane = 2:3); ^1H NMR (500 MHz, CDCl_3) δ 7.66 (d, J = 8.3 Hz, 2H), 7.35-7.28 (m, 3H), 6.89 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 6.81 (ddd, J = 7.6, 1.6, 0.9 Hz, 1H), 6.77 (t, J = 2.1 Hz, 1H), 6.45 (s, 1H), 4.65 (s, 2H), 4.11 (d, J = 0.9 Hz, 2H), 3.81 (s, 3H), 2.44 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3): δ 160.2, 154.6, 145.6, 136.4, 134.8, 130.2, 130.0, 128.6, 128.4, 120.1, 116.1, 113.9, 113.7, 55.3, 54.0, 47.8, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{20}\text{NO}_5\text{S}$: 374.1062; found: 374.1059.

3-(3-Chloro-4-methoxybenzyl)-5-(tosylmethyl)oxazol-2(3H)-one (3g)




3g (39 mg) was synthesized following general procedure A; white solid; 69% yield (eluent: EtOAc/Pentane = 2:3); ^1H NMR (500 MHz, CDCl_3): δ 7.66 (d, J = 8.0 Hz, 2H), 7.32 (app d, J = 8.1 Hz, 3H), 7.14 (dd, J = 8.4, 2.2 Hz, 1H), 6.92 (d, J = 8.4 Hz, 1H), 6.46 (s, 1H), 4.59 (s, 2H), 4.12 (s, 2H), 3.91 (s, 3H), 2.44 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 155.2, 154.4, 145.6, 134.8, 130.0, 129.8, 128.7, 128.4, 128.0, 127.7, 123.1, 115.9, 112.3, 56.2, 53.9, 46.9, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{19}\text{ClNO}_5\text{S}$: 408.0672 and 410.0643; found: 408.0668 and 410.0636.

3-(2-Chlorobenzyl)-5-(tosylmethyl)oxazol-2(3H)-one (3h)




3h (38 mg) was synthesized following general procedure A; white solid; 71% yield (eluent: EtOAc/Pentane = 2:3); ^1H NMR (400 MHz, CDCl_3): δ 7.66 (d, J = 8.3 Hz, 2H), 7.44-7.39 (m, 1H), 7.33-7.26 (m, 5H), 6.54-6.49 (m, 1H), 4.79 (s, 2H), 4.10 (d, J = 1.0 Hz, 2H), 2.42 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3): δ 154.4, 145.6, 134.8, 133.6, 132.5, 130.7, 130.2, 130.0, 128.6, 128.4, 127.5, 116.4, 116.4, 54.0, 45.5, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{17}\text{ClNO}_4\text{S}$: 378.0566 and 380.0537; Found: 378.0562 and 380.0530.

3-(4-Chlorobenzyl)-5-(tosylmethyl)oxazol-2(3H)-one (3i)




3i (37 mg) was synthesized following general procedure A; white solid; 70% yield (eluent: EtOAc/Pentane = 2:3); ^1H NMR (500 MHz, CDCl_3): δ 7.66 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.18 (d, J = 8.5 Hz, 2H), 6.45 (s, 1H), 4.65 (s, 2H), 4.12 (d, J = 1.0 Hz, 2H), 2.45 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3): δ 154.5, 145.6, 134.8, 134.6, 133.5, 130.0, 129.4, 129.3, 128.8, 128.4, 115.9, 53.9, 47.2, 21.7; HRMS: $[\text{M}+\text{Na}]^+$ calculated for $\text{C}_{18}\text{H}_{16}\text{ClNO}_4\text{SNa}$: 400.0386 and 402.0356; found: 400.0380 and 402.0350.

3-(3-Bromobenzyl)-5-(tosylmethyl)oxazol-2(3H)-one (3j)




3j (42 mg) was synthesized following general procedure A; white solid; 72% yield (eluent: EtOAc/Pentane = 2:3); ^1H NMR (400 MHz, CDCl_3): δ 7.65 (d, J = 8.3 Hz, 2H), 7.48 (ddd, J = 7.9, 1.9, 1.1 Hz, 1H), 7.37 (s, 1H), 7.33-7.28 (m, 2H), 7.25-7.21 (m, 1H), 7.19-7.14 (m, 1H), 6.46 (t, J = 0.9 Hz, 1H), 4.63 (s, 2H), 4.11 (s, 2H), 2.43 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 154.5, 145.7, 137.2, 134.8, 131.7, 130.8, 130.7, 130.0, 128.9, 128.4, 126.5, 123.1, 115.9, 53.9, 47.2, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{17}\text{BrNO}_4\text{S}$: 422.0061 and 424.0037; found: 422.0058 and 424.0038.

3-(4-Bromobenzyl)-5-(tosylmethyl)oxazol-2(3H)-one (3k)




3k (44 mg) was synthesized following general procedure A; white solid; 75% yield (eluent: EtOAc/Pentane = 2:3); ^1H NMR (400 MHz, CDCl_3): δ 7.64 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.4 Hz, 2H), 7.28 (dt, J = 7.9, 0.7 Hz, 2H), 7.10 (d, J = 8.4 Hz, 2H), 6.43 (s, 1H), 4.61 (s, 2H), 4.10 (d, J = 1.0 Hz, 2H), 2.43 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 154.5, 145.6, 134.8, 134.0, 132.3, 130.0, 129.6, 128.8, 128.4, 122.7, 115.9, 53.9, 47.2, 21.7; $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{17}\text{BrNO}_4\text{S}$: 422.0061 and 424.0037; found: 422.0056 and 424.0036.

4-((2-Oxo-5-(tosylmethyl)oxazol-3(2H)-yl)methyl)benzonitrile (**3l**)




3l (34 mg) was synthesized following general procedure A; white solid; 65% yield (eluent: EtOAc/Pentane = 2:3); ^1H NMR (400 MHz, CDCl_3) δ 7.67 (app t, $J = 8.3$ Hz, 4H), 7.33 (app dd, $J = 8.1$ Hz, 4H), 6.53 (s, 1H), 4.74 (s, 2H), 4.12 (d, $J = 1.0$ Hz, 2H), 2.44 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 154.5, 145.7, 140.2, 135.0, 132.9, 130.1, 129.1, 128.4, 128.3, 118.1, 116.0, 112.6, 53.8, 47.3, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{17}\text{N}_2\text{O}_4\text{S}$: 369.0909; found: 369.0903.

Methyl 4-((2-oxo-5-(tosylmethyl)oxazol-3(2H)-yl)methyl)benzoate (**3m**)




3m (34 mg) was synthesized following general procedure A; white solid; 61% yield (eluent: EtOAc/Pentane = 1:1); ^1H NMR (400 MHz, CDCl_3): δ 8.03 (d, $J = 8.3$ Hz, 2H), 7.65 (d, $J = 8.3$ Hz, 2H), 7.34-7.25 (m, 4H), 6.45 (s, 1H), 4.72 (s, 2H), 4.11 (d, $J = 1.0$ Hz, 2H), 3.91 (s, 3H), 2.43 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 166.4, 154.5, 145.6, 139.8, 134.8, 130.4, 130.3, 130.0, 128.9, 128.4, 127.7, 116.0, 53.9, 52.3, 47.5, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{20}\text{H}_{20}\text{NO}_6\text{S}$: 402.1011; found: 402.1004.

5-(Tosylmethyl)-3-(3-(trifluoromethyl)benzyl)oxazol-2(3H)-one (**3n**)




3n (37 mg) was synthesized following general procedure A; white solid; 65% yield (eluent: EtOAc/Pentane = 3:7); ^1H NMR (400 MHz, CDCl_3): δ 7.68-7.64 (m, 2H), 7.62 (d, $J = 7.7$ Hz, 1H), 7.54-7.42 (m, 3H), 7.32-7.27 (m, 2H), 6.49 (s, 1H), 4.73 (s, 2H), 4.12 (d, $J = 1.0$ Hz, 2H); ^{13}C NMR (101 MHz, CDCl_3): δ 154.5, 145.7, 136.0, 134.8, 131.6 (app d, $J = 32.5$ Hz), 131.2, 130.0, 129.7, 129.0, 128.4, 125.5 (q, $J = 3.7$ Hz), 124.5 (q, $J = 3.7$ Hz), 123.1 (app d, $J = 272.9$ Hz), 115.9, 53.9, 47.4, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{17}\text{F}_3\text{NO}_4\text{S}$: 412.0830; found: 412.0826.

3-(Furan-2-ylmethyl)-5-(tosylmethyl)oxazol-2(3H)-one (3o)




3o (38 mg) was synthesized following general procedure A; white solid; 82% yield (eluent: EtOAc/Pentane = 3:7); ^1H NMR (400 MHz, CDCl_3): δ 7.66 (d, J = 8.3 Hz, 2H), 7.40 (dd, J = 1.8, 0.9 Hz, 1H), 7.33-7.28 (m, 2H), 6.59 (t, J = 1.0 Hz, 1H), 6.36-6.33 (m, 2H), 4.66 (s, 2H), 4.10 (d, J = 1.0 Hz, 2H), 2.43 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 154.1, 147.8, 145.6, 143.4, 134.9, 130.0, 128.6, 128.4, 116.1, 110.7, 109.7, 54.0, 40.4, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{16}\text{H}_{16}\text{NO}_5\text{S}$: 334.0749; found: 334.0746.

3-Propyl-5-(tosylmethyl)oxazol-2(3H)-one (3p)




3p (25 mg) was synthesized following general procedure A; white solid; 62% yield (eluent: EtOAc/Pentane = 2:3); ^1H NMR (400 MHz, CDCl_3): δ 7.70 (d, J = 8.3 Hz, 2H), 7.39-7.30 (m, 2H), 6.56 (d, J = 0.9 Hz, 1H), 4.14 (d, J = 1.0 Hz, 2H), 3.47 (t, 7.24 Hz, 2H), 2.43 (s, 3H), 1.68-1.59 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 154.6, 145.6, 135.0, 130.0, 128.4, 128.2, 116.5, 77.3, 77.0, 76.7, 54.0, 45.7, 22.1, 21.7, 10.9; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{14}\text{H}_{18}\text{NO}_4\text{S}$: 296.0956; found: 296.0953.

3-Cyclohexyl-5-(tosylmethyl)oxazol-2(3H)-one (3q)




3q (33 mg) was synthesized following general procedure A; white solid; 70% yield (eluent: EtOAc/Pentane = 2:3); ^1H NMR (500 MHz, CDCl_3): δ 7.73-7.67 (m, 2H), 7.34 (d, J = 8.0 Hz, 2H), 6.61 (s, 1H), 4.14 (s, 2H), 3.79 (tt, J = 7.8, 4.0 Hz, 1H), 2.45 (s, 3H), 1.94-1.93 (m, 2H), 1.90-1.82 (m, 2H), 1.73-1.70 (m, 1H), 1.37 (qd, J = 12.1, 6.2 Hz, 4H), 1.22-1.09 (m, 1H); ^{13}C NMR (126 MHz, CDCl_3): δ 154.1, 145.6, 135.0, 130.0, 128.4, 128.3, 113.8, 54.1, 53.4, 32.1, 25.2, 25.0, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{22}\text{NO}_4\text{S}$: 336.1269; Found: 336.1267.

3-Benzyl-4-methyl-5-(tosylmethyl)oxazol-2(3H)-one (**3u**)




3u (28 mg) was synthesized following general procedure A; white solid; 57% yield (eluent: EtOAc/Pentane = 2:3); ^1H NMR (400 MHz, CDCl_3): δ 7.62 (d, J = 8.3 Hz, 2H), 7.38-7.30 (m, 3H), 7.27-7.23 (m, 2H), 7.22-7.17 (m, 2H), 4.70 (s, 2H), 4.11 (s, 2H), 2.40 (s, 3H), 1.77 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 154.9, 145.4, 135.7, 134.8, 130.0, 129.0, 128.4, 128.2, 127.1, 125.4, 123.8, 53.2, 45.5, 21.7, 8.3; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{20}\text{NO}_4\text{S}$: 358.1113; found: 358.1110.

3-Benzyl-6-(tosylmethyl)-3,4-dihydro-2H-1,3-oxazin-2-one (**4a**)




4a (26 mg) was synthesized following general procedure A; white solid; 52% yield (eluent: EtOAc/Pentane = 1:1); ^1H NMR (400 MHz, CDCl_3): δ 7.81-7.72 (m, 2H), 7.37-7.30 (m, 5H), 7.27-7.23 (m, 2H), 5.23 (t, J = 3.4 Hz, 1H), 4.49 (s, 2H), 3.84 (s, 2H), 3.73 (d, J = 3.4 Hz, 2H), 2.43 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 149.4, 145.4, 140.6, 135.5, 135.1, 129.9, 128.8, 128.4, 128.2, 128.1, 102.6, 59.4, 52.1, 44.7, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{24}\text{H}_{22}\text{NO}_4\text{S}$: 358.1113; found: 358.1108.

3-(4-Methylbenzyl)-6-(tosylmethyl)-3,4-dihydro-2H-1,3-oxazin-2-one (**4b**)




4b (26 mg) was synthesized following general procedure A; white solid; 50% yield (eluent: EtOAc/Pentane = 1:1); ^1H NMR (400 MHz, CDCl_3): δ 7.76 (d, J = 8.3 Hz, 2H), 7.33 (d, J = 7.8 Hz, 2H), 7.14 (s, 4H), 5.22 (t, J = 3.4 Hz, 1H), 4.45 (s, 2H), 3.83 (s, 2H), 3.71 (d, J = 3.4 Hz, 2H), 2.44 (s, 3H), 2.34 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 149.4, 145.4, 140.5, 137.9, 135.5, 132.0, 129.9, 129.5, 128.4, 128.2, 102.6, 59.4, 51.8, 44.5, 21.7, 21.1; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{20}\text{H}_{22}\text{NO}_4\text{S}$: 372.1269; found: 372.1266.

3-(2-Chlorobenzyl)-6-(tosylmethyl)-3,4-dihydro-2H-1,3-oxazin-2-one (4c)




4c (24 mg) was synthesized following general procedure A; white solid; 44% yield (eluent: EtOAc/Pentane = 1:1); ^1H NMR (500 MHz, CDCl_3): δ 7.80 (d, J = 8.1 Hz, 2H), 7.41-7.39 (m, 1H), 7.36-7.32 (m, 3H), 7.28 (dd, J = 6.4, 2.7 Hz, 2H), 5.28 (t, J = 3.4 Hz, 1H), 4.67 (s, 2H), 3.87 (s, 2H), 3.82 (d, J = 3.4 Hz, 2H), 2.45 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 149.4, 145.4, 140.7, 135.5, 133.9, 132.6, 129.9, 129.8, 129.5, 129.4, 128.4, 127.3, 102.7, 59.4, 49.3, 45.2, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{19}\text{ClNO}_4\text{S}$: 392.0723 and 394.0694; found: 392.0719 and 394.0689.

3-(3-Bromobenzyl)-6-(tosylmethyl)-3,4-dihydro-2H-1,3-oxazin-2-one (4d)




4d (27 mg) was synthesized following general procedure A; white solid; 45% yield (eluent: EtOAc/Pentane = 1:1); ^1H NMR (400 MHz, CDCl_3): δ 7.77 (d, J = 8.4 Hz, 2H), 7.45 (dt, J = 7.5, 1.8 Hz, 1H), 7.41 (d, J = 1.8 Hz, 1H), 7.37-7.33 (m, 2H), 7.24-7.19 (m, 2H), 5.25 (t, J = 3.4 Hz, 1H), 4.45 (s, 2H), 3.84 (s, 2H), 3.75 (d, J = 3.4 Hz, 2H), 2.44 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 149.3, 145.5, 140.7, 137.5, 135.4, 131.3, 131.0, 130.4, 130.0, 128.4, 126.8, 122.9, 102.5, 59.4, 51.6, 44.9, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{19}\text{BrNO}_4\text{S}$: 436.0218 and 438.0194; found: 436.0210 and 438.0191.

Methyl 4-((2-oxo-6-(tosylmethyl)-2H-1,3-oxazin-3(4H)-yl)methyl)benzoate (4e)




4e (28 mg) was synthesized following general procedure A; white solid; 48% yield (eluent: EtOAc/Pentane = 1:1); ^1H NMR (500 MHz, CDCl_3): δ 8.02 (s, 2H), 7.79 (d, J = 8.0 Hz, 2H), 7.36-7.32 (m, 4H), 5.27 (t, J = 3.4 Hz, 1H), 4.56 (s, 2H), 3.92 (s, 3H), 3.86 (s, 2H), 3.77 (d, J = 3.4 Hz, 2H), 2.45 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 166.6, 149.4, 145.4, 140.7, 140.2, 135.5, 130.1, 130.0, 129.9, 128.4, 127.9, 102.5, 59.4, 52.2, 51.9, 45.0, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{21}\text{H}_{22}\text{NO}_6\text{S}$: 416.1167; found: 416.1161.

6-(Tosylmethyl)-3-(3-(trifluoromethyl)benzyl)-3,4-dihydro-2H-1,3-oxazin-2-one (4f)




4f (23 mg) was synthesized following general procedure A; white solid; 39% yield (eluent: EtOAc/Pentane = 2:3); ^1H NMR (400 MHz, CDCl_3) δ 7.77 (d, $J = 8.4$ Hz, 2H), 7.61-7.54 (m, 1H), 7.52-7.44 (m, 3H), 7.33 (d, $J = 8.1$ Hz, 2H), 5.26 (t, $J = 3.4$ Hz, 1H), 4.55 (s, 2H), 3.85 (s, 2H), 3.77 (d, $J = 3.4$ Hz, 2H), 2.43 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 149.4, 145.5, 140.7, 136.2, 135.5, 131.5, 131.2 (app d, $J = 32.3$ Hz), 129.9, 129.4, 128.4, 125.1 (q, $J = 3.7$ Hz), 124.8 (q, $J = 3.7$ Hz), 123.8 (app d, $J = 272.3$ Hz), 102.5, 59.3, 51.8, 45.0, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{20}\text{H}_{19}\text{F}_3\text{NO}_4\text{S}$: 426.0986; found: 426.0977.

3-Cyclohexyl-6-(tosylmethyl)-3,4-dihydro-2H-1,3-oxazin-2-one (4g)




4g (25 mg) was synthesized following general procedure A; white solid; 51% yield (eluent: EtOAc/Pentane = 1:1); ^1H NMR (400 MHz, CDCl_3): δ 7.77 (d, $J = 8.4$ Hz, 2H), 7.33 (d, $J = 8.0$ Hz, 2H), 5.33-5.25 (m, 1H), 4.04 (ddd, $J = 11.6, 7.8, 3.7$ Hz, 1H), 3.83 (s, 2H), 3.77 (d, $J = 3.5$ Hz, 2H), 2.43 (s, 3H), 1.85-1.75 (m, 2H), 1.69-1.64 (m, 2H), 1.43-1.32 (m, 4H), 1.12-0.99 (m, 1H), 0.86-0.83 (m, 1H); ^{13}C NMR (101 MHz, CDCl_3): δ 148.8, 145.3, 140.2, 135.5, 129.9, 128.4, 102.7, 59.3, 55.6, 39.8, 28.9, 25.5, 25.3, 21.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{24}\text{NO}_4\text{S}$: 350.1426; found: 350.1421.

3-Benzyl-4-methyl-6-(tosylmethyl)-3,4-dihydro-2H-1,3-oxazin-2-one (4h)




4h (18 mg) was synthesized following general procedure A; brown gummy; 36% yield (eluent: EtOAc/Pentane = 2:3); ^1H NMR (400 MHz, CDCl_3): δ 7.77 (d, $J = 8.3$ Hz, 2H), 7.38-7.30 (m, 5H), 7.24 (d, $J = 7.6$ Hz, 2H), 5.24 (d, $J = 4.6$ Hz, 1H), 5.05 (d, $J = 15.2$ Hz, 1H), 4.08 (d, $J = 15.3$ Hz, 1H), 3.87 (s, 2H), 3.83 (dd, $J = 6.5, 5.0$ Hz, 1H), 2.45 (s, 3H), 1.23 (d, $J = 6.4$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3): δ 149.9, 145.4, 139.8, 135.7, 135.2, 129.9, 128.8, 128.5, 128.0, 127.9, 108.9, 77.3, 77.0, 76.7, 59.3, 49.9, 49.1, 21.7, 20.6; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{20}\text{H}_{22}\text{NO}_4\text{S}$: 372.1269; found: 372.1266.

3-Benzyl-6-(((4-chlorophenyl)sulfonyl)methyl)-3,4-dihydro-2H-1,3-oxazin-2-one (4i)




4i (18 mg) was synthesized following general procedure A; white solid; 42% yield (eluent: EtOAc/Pentane = 1:1); ^1H NMR (400 MHz, CDCl_3): δ 7.83 (d, $J = 8.7$ Hz, 2H), 7.51 (d, $J = 8.8$ Hz, 2H), 7.39-7.31 (m, 3H), 7.25 (d, $J = 6.3$ Hz, 2H), 5.24 (t, $J = 3.4$ Hz, 1H), 4.49 (s, 2H), 3.86 (s, 2H), 3.74 (d, $J = 3.4$ Hz, 2H); ^{13}C NMR (101 MHz, CDCl_3): δ 149.2, 141.2, 140.3, 136.9, 135.0, 129.9, 129.6, 128.9, 128.2, 128.2, 103.0, 59.5, 52.2, 44.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{17}\text{ClNO}_4\text{S}$: 378.0566 and 380.0537; found: 378.0563 and 380.0532.

3-Benzyl-6-(((4-fluorophenyl)sulfonyl)methyl)-3,4-dihydro-2H-1,3-oxazin-2-one (4j)



4j (15 mg) was synthesized following general procedure A; white solid; 38% yield (eluent: EtOAc/Pentane = 1:1); ^1H NMR (500 MHz, CDCl_3) δ 7.99-7.87 (m, 2H), 7.41-7.31 (m, 3H), 7.28-7.26 (m, 2H), 7.25-7.19 (m, 2H), 5.26 (t, $J = 3.4$ Hz, 1H), 4.51 (s, 2H), 3.88 (s, 2H), 3.76 (d, $J = 3.5$ Hz, 2H); ^{13}C NMR (126 MHz, CDCl_3): δ 166.2 (d, $J = 257.6$ Hz), 149.2, 140.4, 135.0, 134.4, 131.2 (d, $J = 9.9$ Hz), 128.9, 128.3, 116.8, 116.6, 102.9, 59.6, 52.2, 44.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{17}\text{FNO}_4\text{S}$: 362.0862; found: 362.0858.

3-Benzyl-6-((phenylsulfonyl)methyl)-3,4-dihydro-2H-1,3-oxazin-2-one (4k):



4j (18 mg) was synthesized following general procedure A; white solid; 49% yield (eluent: EtOAc/Pentane = 1:1); ^1H NMR (500 MHz, CDCl_3): δ 7.95 – 7.88 (m, 2H), 7.72 – 7.65 (m, 1H), 7.60 – 7.53 (m, 2H), 7.38-7.33 (m, 3H), 7.28 – 7.24 (m, 2H), 5.26 (t, $J = 3.4$ Hz, 1H), 4.50 (s, 2H), 3.88 (s, 2H), 3.75 (d, $J = 3.5$ Hz, 2H); ^{13}C NMR (126 MHz, CDCl_3): δ 149.3, 140.4, 138.4, 135.1, 134.3, 129.3, 128.8, 128.4, 128.2, 128.2, 102.8, 59.4, 52.1, 44.7; HRMS: $[\text{M}+\text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{18}\text{NO}_4\text{S}$: 344.0956; Found: 344.0953.

3. Intermediate trapping experiment

3.a HRMS analysis of reaction mixture

General Procedure A was followed except except the reaction was quenched after 5 hours. After completion of the reaction, the reaction mixture was directly analysed by HRMS.




Fig. S2. HRMS spectra.

5. X-ray crystallographic studies

a) X-ray crystallographic studies of compound **3a** (CCDC 2287477)

A single crystals of compound **3a** for X-ray diffraction analysis were grown using CHCl_3 solvent under slow evaporation method.




Fig. S3. Asymmetric unit, showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level.

Experimental:

Data were obtained at a temperature of 92(6) K in a SuperNova, Dual, Cu at home/near four-circle diffractometer with a microfocus sealed X-ray tube, using a mirror as a monochromator and an Atlas detector and with Cu $K\alpha$ radiation ($\lambda = 1.54184 \text{ \AA}$).

All data were integrated with CrysAlisPro and a gaussian absorption correction using SCALE3 ABSPACK was applied. All structures was solved by dual methods using SHELXT and refined by full-matrix least-squares methods against F^2 by SHELXL using OLEX2 as an interface.

Table 1. Crystal data and structure refinement for **3a**

CCDC	2287477
Empirical formula	C ₁₈ H ₁₇ NO ₄ S
Formula weight	343.38
Temperature [K]	104.4(5)
Crystal system	monoclinic
Space group (number)	$P2_1/c$ (14)
a [Å]	12.30520(10)
b [Å]	7.33200(10)
c [Å]	18.7530(2)
α [°]	90
β [°]	102.2920(10)
γ [°]	90
Volume [Å ³]	1653.14(3)
Z	4

ρ_{calc} [gcm⁻³]	1.380
μ [mm⁻¹]	1.933
F(000)	720
Crystal size [mm³]	0.18×0.12×0.05
Crystal colour	translucent intense colourless
Crystal shape	block
Radiation	Cu K α (λ =1.54184 Å)
2θ range [°]	7.35 to 145.37 (0.81 Å)
Index ranges	-15 ≤ h ≤ 15 -9 ≤ k ≤ 8 -23 ≤ l ≤ 19
Reflections collected	22109
Independent reflections	3235 R _{int} = 0.0364 R _{sigma} = 0.0185
Completeness to θ = 67.684°	99.9 %
Data / Restraints / Parameters	3235/0/218
Goodness-of-fit on F²	1.040
Final R indexes [I ≥ 2σ(I)]	R1 = 0.0322 wR2 = 0.0832
Final R indexes [all data]	R1 = 0.0377 wR2 = 0.0877
Largest peak/hole [eÅ⁻³]	0.45/-0.48

b) X-ray crystallographic studies of compound 4a (CCDC 2287478)

A single crystals of compound 3a for X-ray diffraction analysis were grown using CHCl₃ solvent under slow evaporation method.




Fig. S4. Asymmetric unit, showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level.

Table 2. Crystal data and structure refinement for **4a**



CCDC	2287478
Empirical formula	C19H19NO4S
Formula weight	357.41
Temperature [K]	104.60(14)
Crystal system	orthorhombic
Space group (number)	$P2_12_12_1$ (19)
a [Å]	7.37430(10)
b [Å]	15.0097(2)
c [Å]	15.6382(2)
α [°]	90
β [°]	90
γ [°]	90
Volume [Å³]	1730.93(4)
Z	4
ρ_{calc} [gm⁻³]	1.372
μ [mm⁻¹]	1.867
F(000)	752
Crystal size [mm³]	0.34×0.22×0.15
Crystal colour	metallic dark yellow
Crystal shape	block
Radiation	Cu K α ($\lambda=1.54184$ Å)
2θ range [°]	8.16 to 145.27 (0.81 Å)
Index ranges	$-8 \leq h \leq 6$ $-18 \leq k \leq 18$ $-18 \leq l \leq 19$
Reflections collected	16147
Independent reflections	3386 R _{int} = 0.0314 R _{sigma} = 0.0213
Completeness to $\theta = 67.684^\circ$	100.0 %

Data / Restraints / Parameters	3386/0/227
Goodness-of-fit on F2	1.064
Final R indexes [I\geq2σ(I)]	R1 = 0.0270 wR2 = 0.0682
Final R indexes [all data]	R1 = 0.0293 wR2 = 0.0703
Largest peak/hole [e\AA⁻³]	0.22/-0.26
Flack X parameter	-0.004(7)


5. References:

1. Q.-W. Song and L.-N. He, *Adv. Synth. Catal.*, 2016, **358**, 1251–1258.
2. W. Hess and J. W. Burton, *Chem.-Eur., J.* 2010, **16**, 12303– 12306.
3. P. Quinodoz, A. Quelhas, K. Wright, B. Drouillat, J. Marrot and F. Couty, *Eur. J. Org. Chem.*, 2017, **2017**, 2621– 2626.


6. Copies of ^1H and ^{13}C NMR spectra:





^1H (400 MHz) spectrum of compound 3a in CDCl_3





^{13}C (101 MHz) spectrum of compound 3a in CDCl_3





¹H (500 MHz) spectrum of compound 3b in CDCl₃



¹³C (126 MHz) spectrum of compound 3b in CDCl₃





¹H (400 MHz) spectrum of compound 3c in CDCl₃




^{13}C (101 MHz) spectrum of compound 3c in CDCl_3

S24





^1H (500 MHz) spectrum of compound 3d in CDCl_3



S25





^{13}C (126 MHz) spectrum of compound 3d in CDCl_3





^1H (400 MHz) spectrum of compound 3e in CDCl_3



^{13}C (101 MHz) spectrum of compound 3e in CDCl_3





¹H (500 MHz) spectrum of compound 3f in CDCl₃




^{13}C (126 MHz) spectrum of compound 3f in CDCl_3

S30




¹H (500 MHz) spectrum of compound 3g in CDCl₃

S31




^{13}C (101 MHz) spectrum of compound 3g in CDCl_3





^1H (400 MHz) spectrum of compound 3h in CDCl_3

S33





¹³C (126 MHz) spectrum of compound 3h in CDCl₃

S34





¹H (500 MHz) spectrum of compound 3i in CDCl₃

S35





^{13}C (126 MHz) spectrum of compound 3i in CDCl_3

S36




^1H (400 MHz) spectrum of compound 3j in CDCl_3

S37





^{13}C (101 MHz) spectrum of compound 3j in CDCl_3

S38





¹H (400 MHz) spectrum of compound 3k in CDCl₃




^{13}C (101 MHz) spectrum of compound 3k in CDCl_3

S40





¹H (400 MHz) spectrum of compound 31 in CDCl₃

S41





^{13}C (101 MHz) spectrum of compound 3l in CDCl_3

S42





^1H (400 MHz) spectrum of compound 3m in CDCl_3


S43




¹³C (101 MHz) spectrum of compound 3m in CDCl₃



^1H (400 MHz) spectrum of compound 3n in CDCl_3




¹³C (101 MHz) spectrum of compound 3n in CDCl₃




^1H (400 MHz) spectrum of compound 3o in CDCl_3


S47



^{13}C (101 MHz) spectrum of compound 3o in CDCl_3




^1H (400 MHz) spectrum of compound 3p in CDCl_3





^{13}C (101 MHz) spectrum of compound 3p in CDCl_3

S50




^1H (500 MHz) spectrum of compound 3q in CDCl_3




^{13}C (126 MHz) spectrum of compound 3q in CDCl_3

S52





^1H (400 MHz) spectrum of compound 3u in CDCl_3

S53




^{13}C (101 MHz) spectra of compound 3u in CDCl_3




^1H (400 MHz) spectrum of compound 4a in CDCl_3

S55




^{13}C (101 MHz) spectrum of compound 4a in CDCl_3





¹H (400 MHz) spectrum of compound 4b in CDCl₃

S57




^{13}C (101 MHz) spectrum of compound 4b in CDCl_3

S58




^1H (500 MHz) spectrum of compound 4c in CDCl_3




^{13}C (101 MHz) spectrum of compound 4c in CDCl_3

S60





^1H (400 MHz) spectrum of compound 4d in CDCl_3

S61




^{13}C (101 MHz) spectrum of compound 4d in CDCl_3

S62





¹H (500 MHz) spectrum of compound 4e in CDCl₃

S63





S64





¹H (400 MHz) spectrum of compound 4f in CDCl₃

S65




^{13}C (101 MHz) spectrum of compound 4f in CDCl_3

S66





^1H (400 MHz) spectrum of compound 4g in CDCl_3

S67





^{13}C (101 MHz) spectrum of compound 4g in CDCl_3

S68




¹H (400 MHz) spectrum of compound 4h in CDCl₃


S69



^{13}C (101 MHz) spectrum of compound 4h in CDCl_3




7.84
7.82
7.52
7.50
7.37
7.36
7.36
7.35
7.35
7.34
7.34
7.33
7.33
7.32
7.32
7.26
7.26
7.24
7.24
5.25
5.24
5.24
4.49
3.86
3.75
3.74




^1H (400 MHz) spectrum of compound 4i in CDCl_3

S71




¹³C (101 MHz) spectrum of compound 4i in CDCl₃

S72




7.94
7.93
7.92
7.91
7.88
7.37
7.36
7.36
7.35
7.35
7.34
7.33
7.28
7.27
7.26
7.26
7.26
7.24
7.24
7.23
7.23
7.22
7.22
7.21
5.27
5.26
4.51
3.88
3.77
3.76




^1H (500 MHz) spectrum of compound 4j in CDCl_3

S73




^{13}C (126 MHz) spectrum of compound 4j in CDCl_3

S74



^1H (500 MHz) spectrum of compound 4k in CDCl_3

S75



¹³C (126 MHz) spectrum of compound 4k in CDCl₃

S76